BR112015008380A2 - uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética - Google Patents

uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética

Info

Publication number
BR112015008380A2
BR112015008380A2 BR112015008380A BR112015008380A BR112015008380A2 BR 112015008380 A2 BR112015008380 A2 BR 112015008380A2 BR 112015008380 A BR112015008380 A BR 112015008380A BR 112015008380 A BR112015008380 A BR 112015008380A BR 112015008380 A2 BR112015008380 A2 BR 112015008380A2
Authority
BR
Brazil
Prior art keywords
pyrazol
tetrasubstituted
treatment
amino
methyl
Prior art date
Application number
BR112015008380A
Other languages
English (en)
Portuguese (pt)
Inventor
Gale Jeremy
Tamimi Nihad
Clerin Valerie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112015008380A2 publication Critical patent/BR112015008380A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112015008380A 2012-10-23 2013-10-09 uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética BR112015008380A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717429P 2012-10-23 2012-10-23
PCT/IB2013/059239 WO2014064566A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Publications (1)

Publication Number Publication Date
BR112015008380A2 true BR112015008380A2 (pt) 2017-07-04

Family

ID=49765599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008380A BR112015008380A2 (pt) 2012-10-23 2013-10-09 uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética

Country Status (15)

Country Link
US (2) US20150274735A1 (https=)
EP (1) EP2911672A1 (https=)
JP (1) JP2015534977A (https=)
KR (1) KR20150056853A (https=)
CN (1) CN104755086A (https=)
AU (1) AU2013336293B2 (https=)
BR (1) BR112015008380A2 (https=)
CA (1) CA2888160A1 (https=)
HK (1) HK1211850A1 (https=)
IL (1) IL238374A0 (https=)
IN (1) IN2015DN03190A (https=)
MX (1) MX2015005004A (https=)
RU (1) RU2015115005A (https=)
SG (1) SG11201502286XA (https=)
WO (1) WO2014064566A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939328B1 (ko) * 2012-12-21 2019-01-16 주식회사 엘지화학 신규한 구조를 가지는 중공사막 및 그 제조 방법
EP3925957A4 (en) 2019-02-15 2022-11-02 Tohoku University 1,3-DIOXOLANE DERIVATIVE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
SI1881985T1 (sl) * 2005-05-12 2011-03-31 Pfizer Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida
CA2608018C (en) * 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.

Also Published As

Publication number Publication date
CA2888160A1 (en) 2014-05-01
WO2014064566A1 (en) 2014-05-01
US20160136170A1 (en) 2016-05-19
AU2013336293A1 (en) 2015-04-09
JP2015534977A (ja) 2015-12-07
KR20150056853A (ko) 2015-05-27
MX2015005004A (es) 2015-07-17
SG11201502286XA (en) 2015-05-28
CN104755086A (zh) 2015-07-01
HK1211850A1 (en) 2016-06-03
IN2015DN03190A (https=) 2015-10-02
EP2911672A1 (en) 2015-09-02
AU2013336293B2 (en) 2016-05-12
US20150274735A1 (en) 2015-10-01
RU2015115005A (ru) 2016-12-20
IL238374A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
MD4575B1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA202090662A3 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UA117122C2 (uk) Хінолонові похідні
MX340985B (es) Compuestos de n-heteroarilo.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
PH12012502082A1 (en) Combination of active loaded granules with additional actives
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
WO2012145575A3 (en) Therapy for leukemia
BR112015008380A2 (pt) uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética
EA201791354A2 (ru) Препараты производных пиримидиндиона
BR112013024196A2 (pt) complexos de gálio, composições farmacêuticas e métodos de uso
IN2014DN10134A (https=)
EA201590415A1 (ru) Производные диазепинона, применимые для лечения синдрома хрупкой х-хромосомы, болезни паркинсона или рефлюксного заболевания
MY166556A (en) Pharmaceutical formulation for topical administration comprising b220
BR112015028551A2 (pt) derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos
BR112014013723A2 (pt) formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]